surgoncoКреативная хирургия и онкологияCreative surgery and oncology2076-30932307-0501Башкирский государственный медицинский университет10.24060/2076-3093-2019-9-1-87-88surgonco-368Research ArticleКРАТКИЕ СООБЩЕНИЯBRIEF COMMUNICATIONSПерспективы ингибирования NF-kappa B внутрибрюшинным введением DHMEQImportance of Novel Intraperitoneal Therapy of NF-kappa B Inhibitor DHMEQhttps://orcid.org/0000-0003-2047-963XГанцевШ. Х.GantsevSh. Kh.

Ганцев Шамиль Ханафиевич — д.м.н., профессор, зав. кафедрой онкологии с курсами онкологии и патологической анатомии ИДПО, 

450008, Уфа, ул. Ленина, 3

 

Gantsev Shamil — Doctor of Medical Sciences, Professor, Head of the Department of Oncology with Oncology and Anatomical Pathology courses in the Institute of Additional Professional Education

3 Lenin str., Ufa, 450008

 

prfg@mail.ruУмезаваК.UmezawaKazuo

Умезава Казуо — профессор кафедры целевой молекулярной медицины,

Нагакуте, Айчи, Язакокаримата, 1-1

Umezawa Kazuo — Professor of the Department of Molecular Target Medicine Screening

 

Башкирский государственный медицинский университетРоссияBashkir State Medical UniversityRussian FederationМедицинский университет Айчи, ЯпонияЯпонияAichi Medical UniversityJapan201925042019918788Copyright © Ганцев Ш.Х., Умезава К., 20192019Ганцев Ш.Х., Умезава К.Gantsev S.K., Umezawa K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgonco.ru/jour/article/view/368

.

.

NF-kappa BcancerleukemiadehydroxymethylepoxyquinomicinDHMEQNF-kappa BcancerleukemiadehydroxymethylepoxyquinomicinDHMEQReferencesAriga A., Namekawa J., Matsumoto N., Inoue J., Umezawa K. Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem. 2002;277(27):24625–30. DOI: 10.1074/jbc.M112063200Ariga A., Namekawa J., Matsumoto N., Inoue J., Umezawa K. Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem. 2002;277(27):24625–30. DOI: 10.1074/jbc.M112063200Yamamoto M., Horie R., Takeiri M., Kozawa I., Umezawa K. Inactivation of nuclear factor kappa B components by covalent binding of (−)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem. 2008;51(18):5780–8. DOI: 10.1021/jm8006245Yamamoto M., Horie R., Takeiri M., Kozawa I., Umezawa K. Inactivation of nuclear factor kappa B components by covalent binding of (−)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem. 2008;51(18):5780–8. DOI: 10.1021/jm8006245Lin Y., Ukaji T., Koide N., Umezawa K. Inhibition of late and early phases of cancer metastasis by NF-κB inhibitor DHMEQ derived from microbial bioactive metabolite epoxyquinomicin: A review. Int J Mol Sci. 2018;19(3):729. DOI: 10.3390/ijms19030729Lin Y., Ukaji T., Koide N., Umezawa K. Inhibition of late and early phases of cancer metastasis by NF-κB inhibitor DHMEQ derived from microbial bioactive metabolite epoxyquinomicin: A review. Int J Mol Sci. 2018;19(3):729. DOI: 10.3390/ijms19030729Umezawa K. Possible role of peritoneal NF-κB in peripheral inflammation and cancer: Lessons from the inhibitor DHMEQ. Biomed Pharmacother. 2011;65(4):252–9. DOI: 10.1016/j.biopha.2011.02.003Umezawa K. Possible role of peritoneal NF-κB in peripheral inflammation and cancer: Lessons from the inhibitor DHMEQ. Biomed Pharmacother. 2011;65(4):252–9. DOI: 10.1016/j.biopha.2011.02.003Umezawa K. Peritoneal NF-κB as a possible molecular target for suppression of various cancers and inflammation. (Review) Forum Immunopathol Dis Therap. 2013;4(1):63–77. DOI: 10.1615/ForumImmunDisTher.2013008314Umezawa K. Peritoneal NF-κB as a possible molecular target for suppression of various cancers and inflammation. (Review) Forum Immunopathol Dis Therap. 2013;4(1):63–77. DOI: 10.1615/ForumImmunDisTher.2013008314Sosinnska P., Macckowiak B., Staniszewski R., Umezawa K., Breborowicz A. Inhibition of NF-κB with dehydroxyepoxiquinomicin modifies function of human peritoneal mesothelial cells. Am J Transl Res. 2016;8(12):5756–5. PMID: 28078047Sosinnska P., Macckowiak B., Staniszewski R., Umezawa K., Breborowicz A. Inhibition of NF-κB with dehydroxyepoxiquinomicin modifies function of human peritoneal mesothelial cells. Am J Transl Res. 2016;8(12):5756–5. PMID: 28078047

The authors declare that there are no conflicts of interest present.